Bringing the fundamentals into focus…
Back to Ginkgo Bioworks Holdings, Inc.
How Ginkgo Bioworks Holdings, Inc. stacks up
DNA · against 486 other Healthcare companies of similar size
Valuation
45/ 100
Below the middle of the pack.
Ranked #256 of 487 · scores higher than 46% of peers
Bars: peers in each 10-point band of the valuation score44 peers with a valuation score of 40–49, including DNA · Click a bar to see the companies
Why valuation scores 45?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- lower earnings for the price paid: weaker than 94% of peers. Earnings yield: 3.2% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -31.7% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -25.5% vs peer median 0.0%
Metric by metric
Position: dot = DNA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | DNA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 476 reported | -47.0% | 1.0% | 2% | 30% | |
| EBITDA yieldHigher is better · 492 reported | -31.7% | 3.7% | 8% | 50% | |
| Free cash flow yieldHigher is better · 200 reported | -24.1% | -3.7% | 8% | 20% | |
| Book yieldHigher is better · 484 reported | 61.3% | 45.4% | 65% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around DNAScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score